Company:  I-MAB (IMAB)
Form Type:  F-1/A
Filing Date:  1/14/2020 
CIK:  0001778016 
Address:  SUITE 802, WEST TOWER, OMNLVISION
88 SHANGKE ROAD, PUDONG DISTRICT
 
City, State, Zip:  SHANGHAI,  201210 
Telephone:  862160578000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$22.08  
Change: 
-2.84 (-11.40%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$2.94B
Trade IMAB now with 

© 2020  
Description of Business
We commenced our operations in November 2014, when our predecessor Third Venture Biopharma (Nanjing) Co., Ltd ("Third Venture") was established. I-Mab was incorporated in June 2016 under the laws of the Cayman Islands as our offshore holding company. In July 2016, I-Mab established I-Mab Biopharma Hong Kong Limited ("I-Mab Hong Kong"), as its intermediary holding company. In August 2016, I-Mab Hong Kong established a wholly-owned PRC subsidiary, I-Mab Biopharma (Shanghai) Co., Ltd. ("I-Mab Shanghai"). In September 2016, the assets and operations of Third Venture were consolidated into I-Mab Shanghai. In July 2017, I-Mab Hong Kong acquired a controlling interest in I-Mab Bio-tech (Tianjin) Co., Ltd. ("I-Mab Tianjin"), formerly known as Tasgen Bio-tech (Tianjin) Co., Ltd., a company focused on CMC management of biologics in China.
Register and access this filing in:     
  FORM F-1/A
    CALCULATION OF REGISTRATION FEE
    EXPLANATORY NOTE
    PART II
      Item 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
      Item 7. RECENT SALES OF UNREGISTERED SECURITIES.
      Item 8. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
      Item 9. UNDERTAKINGS.
    EXHIBIT INDEX
    SIGNATURES
  EXHIBIT 1.1
    CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES ...
    Directors, Executive Officers and Others Signing Lock-up ...